Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roni Haklai

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
International Journal of Cancer|April 19, 2011
Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosisVictoria Makovski, Roni Haklai, Yoel Kloog
Journal of Pharmaceutical Sciences|July 13, 2010
Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitroAmir Kraitzer, Yoel Kloog, Roni Haklai, et al.
Methods in Enzymology|April 1, 2008
The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancerBarak Rotblat, Marcello Ehrlich, Roni Haklai, et al.
The Journal of Biological Chemistry|June 19, 2004
Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activityGalit Elad-Sfadia, Roni Haklai, Eyal Balan, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2007
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude miceRoni Haklai, Galit Elad-Sfadia, Yaakov Egozi, et al.
The Enzymes|July 19, 2014
Ras chaperones: new targets for cancer and immunotherapyYoel Kloog, Galit Elad-Sfadia, Roni Haklai, et al.
Oncotarget|March 27, 2013
Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor SalirasibRaya Faigenbaum, Roni Haklai, Gilad Ben-Baruch, et al.
Cellular Signalling|February 11, 2026
Oncogenic crosstalk between ErbB2, nucleolin and RasGal Zysman, Adva Kochavi, Roni Haklai, et al.
Cancer Research|February 21, 2006
Ras and its signals diffuse through the cell on randomly moving nanoparticlesBarak Rotblat, Ofer Yizhar, Roni Haklai, et al.
Journal of Medicinal Chemistry|December 17, 2008
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice modelsLiat Goldberg, Roni Haklai, Victor Bauer, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
International Journal of Cancer|April 19, 2011
Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosisVictoria Makovski, Roni Haklai, Yoel Kloog
Journal of Pharmaceutical Sciences|July 13, 2010
Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitroAmir Kraitzer, Yoel Kloog, Roni Haklai, et al.
Methods in Enzymology|April 1, 2008
The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancerBarak Rotblat, Marcello Ehrlich, Roni Haklai, et al.
The Journal of Biological Chemistry|June 19, 2004
Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activityGalit Elad-Sfadia, Roni Haklai, Eyal Balan, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2007
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude miceRoni Haklai, Galit Elad-Sfadia, Yaakov Egozi, et al.
The Enzymes|July 19, 2014
Ras chaperones: new targets for cancer and immunotherapyYoel Kloog, Galit Elad-Sfadia, Roni Haklai, et al.
Oncotarget|March 27, 2013
Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor SalirasibRaya Faigenbaum, Roni Haklai, Gilad Ben-Baruch, et al.
Cellular Signalling|February 11, 2026
Oncogenic crosstalk between ErbB2, nucleolin and RasGal Zysman, Adva Kochavi, Roni Haklai, et al.
Cancer Research|February 21, 2006
Ras and its signals diffuse through the cell on randomly moving nanoparticlesBarak Rotblat, Ofer Yizhar, Roni Haklai, et al.
Journal of Medicinal Chemistry|December 17, 2008
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice modelsLiat Goldberg, Roni Haklai, Victor Bauer, et al.
Pageof 3